GlassScriptPhysician profile
William Chase Thornbury
NPI 1417027525
$7,853.37
in general payments reported to CMS, 2019-2025
45 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2020: $984 · 2021: $1,084 · 2022: $1,344 · 2023: $1,129 · 2024: $1,137 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,433.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,056.00 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $918.27 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $801.85 | 2019-2025 | |
| Abbvie INC. | $440.04 | 2021-2025 | Ubrelvy, Qulipta |
| Amgen INC. | $384.43 | 2019-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $383.67 | 2021-2025 | |
| Glaxosmithkline, LLC. | $324.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $304.46 | 2019-2022 | |
| Lilly USA, LLC | $294.26 | 2019-2025 | Mounjaro, Jardiance |
| Axsome Therapeutics, INC. | $265.42 | 2023-2025 | Auvelity |
| Shield Therapeutics INC | $256.28 | 2023-2024 | Accrufer |
| Janssen Pharmaceuticals, INC | $238.22 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $192.89 | 2019-2021 | |
| Radius Health, INC. | $190.10 | 2019-2025 | Tymlos |
| Mylan Specialty L.P. | $185.63 | 2019-2024 | Yupelri |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Thornbury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.